An HIV vaccine—evolving concepts
MI Johnston, AS Fauci - New England Journal of Medicine, 2007 - Mass Medical Soc
MI Johnston, AS Fauci
New England Journal of Medicine, 2007•Mass Medical SocThe unique features of the human immunodeficiency virus (HIV) envelope protein have
thwarted efforts to identify a protective vaccine. However, a vaccine that does not prevent
infection but reduces HIV levels and preserves memory CD4+ T cells could benefit both the
recipient and the community at risk. Several vaccines that induce T-cell responses are now
in early clinical trials. This review summarizes the science and strategies in the search for an
effective vaccine to control HIV infection.
thwarted efforts to identify a protective vaccine. However, a vaccine that does not prevent
infection but reduces HIV levels and preserves memory CD4+ T cells could benefit both the
recipient and the community at risk. Several vaccines that induce T-cell responses are now
in early clinical trials. This review summarizes the science and strategies in the search for an
effective vaccine to control HIV infection.
The unique features of the human immunodeficiency virus (HIV) envelope protein have thwarted efforts to identify a protective vaccine. However, a vaccine that does not prevent infection but reduces HIV levels and preserves memory CD4+ T cells could benefit both the recipient and the community at risk. Several vaccines that induce T-cell responses are now in early clinical trials. This review summarizes the science and strategies in the search for an effective vaccine to control HIV infection.
The New England Journal Of Medicine